

TCG Lifesciences appoints Chris H Senanayake as CSO

16 January 2020 | News

Chris is a globally recognized pharma industry innovator and opinion leader in the field of chemical research and development



TCG Lifesciences, a company promoted by New York based Purnendu Chatterjee Group, has announced the induction of Chris Senanayake, as Chief Scientific Officer (CSO) responsible for delivering highest quality scientific solutions and innovations to its global client base.

Chris is a globally recognized pharma industry innovator and opinion leader in the field of chemical research and development. In his last assignment, he was the Vice President in Boehringer Ingelheim Pharmaceutical and led the Chemical Development wing in their USA office. He directed chemical process research and development on an international level and provided leadership to US Chemical Development, Global NCE development in a timely and economical manner.

Swapn Bhattacharya, Managing Director, TCG Lifesciences commented, "Dr. Senanayake demonstrates the ability to define and optimize chemical research and development strategies and tactics. He is able to "connect the dots" between the purely scientific and commercial perspectives and set up creative and effective. We are delighted to welcome Chris into our leadership team and to leverage his expertise and experience to improve our scientific skills and deliver innovative solutions."

"TCG Lifesciences is science based company with strong expertise in medicinal chemistry, scale up and analytical sciences. I am looking forward to working with the highly talented and passionate team to improve their process development offerings by employing innovative process technologies and green chemistry applications", said Chris Senanayake.